Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques

To cope with the decline in COVID-19 vaccine-induced immunity caused by emerging SARS-CoV-2 variants, a heterologous immunization regimen using chimpanzee adenovirus vectored vaccine expressing SARS-CoV-2 spike (ChAd-S) and an inactivated vaccine (IV) was tested in mice and non-human primates (NHPs)...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Qian, Mao, Qunying, Zhang, Jialu, Gao, Fan, Bai, Yu, Cui, Bopei, Liu, Jianyang, An, Chaoqiang, Wang, Qian, Yan, Xujia, Yang, Jinghuan, Song, Lifang, Song, Ziyang, Liu, Dong, Yuan, Yadi, Sun, Jing, Zhao, Jincun, Bian, Lianlian, Wu, Xing, Huang, Weijin, Li, Changgui, Wang, Junzhi, Liang, Zhenglun, Xu, Miao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428284/
https://www.ncbi.nlm.nih.gov/pubmed/36059554
http://dx.doi.org/10.3389/fimmu.2022.949248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428284/
https://www.ncbi.nlm.nih.gov/pubmed/36059554
http://dx.doi.org/10.3389/fimmu.2022.949248

Ejemplares similares